Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2023

19-07-2023 | Myelodysplastic Syndrome | Letter to the Editor

Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?

Authors: Alice Di Rocco, Martina Di Palma, Gianna Maria D’Elia, Giovanni Iaquinta, Massimo Breccia, Francesca Mancini, Paola Grammatico, Maurizio Martelli

Published in: Annals of Hematology | Issue 10/2023

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439–448CrossRefPubMedPubMedCentral
2.
Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544CrossRefPubMedPubMedCentral
3.
Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP et al (2019) Tisagenlecleucel in adult replased or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56CrossRefPubMed
4.
Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL et al (2018) Chimeric antigen receptor T-cell therapy assessment and management of toxicities. Nat Rev Clin Oncol 15(1):47–62CrossRefPubMed
5.
Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF et al (2017) Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov 7(12):1404–1419CrossRefPubMedPubMedCentral
6.
Chakraborty R, Hill BT, Majeed A, Majhail NS (2021) Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies. Transplant Cell Ther 27(3):222–229CrossRefPubMed
7.
Strati P, Adkins S, Nastoupil LJ, Westlin J, Hagemeister FB, Fowler NH et al (2019) Hematopoietic recovery and immune reconstitution after axi-cel CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma. J Clin Oncol 37(15):7545CrossRef
8.
Cordeiro A, Bezerra ED, Hirayama AV, Hill JA, Wu V, Voutsinas J et al (2020) Late events after treatment with CD19-targeted chimeric antigen receptor modified T-cells. Biol Blood Marrow Transplant 26(1):26–33CrossRefPubMed
Metadata
Title
Myelodysplastic clones arising post chimeric antigen receptor t cell therapy (car-t) procedure: a casuality or a new entity?
Authors
Alice Di Rocco
Martina Di Palma
Gianna Maria D’Elia
Giovanni Iaquinta
Massimo Breccia
Francesca Mancini
Paola Grammatico
Maurizio Martelli
Publication date
19-07-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05329-9

Other articles of this Issue 10/2023

Annals of Hematology 10/2023 Go to the issue

Original Article

Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Original Article

Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry

Letter to the Editor

Brentuximab vedotin for Hodgkin lymphoma with hepatic impairment

Letter to the Editor

More than 2% circulating plasma cells as a prognostic biomarker in a large cohort of patients with newly-diagnosed multiple myeloma

Original Article

Association between ABO blood groups and SARS-CoV-2 infection in blood donors of Puglia region

Original Article

The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma—a pooled trials analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits